The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.
Read all of this leaflet carefully before you start using this medicine because it contains important information for you.
– Keep this leaflet. You may need to read it again.
– If you have any further questions, ask your doctor, pharmacist or nurse.
– This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
– If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. See section 4.
1. What Saxenda® is and what it is used for
2. What you need to know before you use Saxenda®
3. How to use Saxenda®
4. Possible side effects
5. How to store Saxenda®
6. Contents of the pack and other information
What Saxenda® is
Saxenda® is a weight loss medicine that contains the active substance liraglutide. It is similar to a natural occurring hormone called glucagon-like peptide-1 (GLP-1 ) that is released from the intestine after a meal. Saxenda® works by acting on receptors in the brain that control your appetite, causing you to feel fuller and less hungry. This may help you eat less food and reduce your body weight.
What Saxenda® is used for
Saxenda® is used for weight loss in addition to diet and exercise in adults aged 18 and above who have
• a BMI of 30 kg/m² or greater (obesity) or
• a BMI of 27 kg/m² and less than 30 kg/m² (overweight) and weight-related health problems (such as diabetes, high blood pressure, abnormal levels of fats in the blood or breathing problems during sleep called ‘obstructive sleep apnoea’).
BMI (Body Mass Index) is a measure of your weight in relation to your height.
You should only continue using Saxenda® if you have lost at least 5% of your initial body weight after 12 weeks on the 3.0 mg/day dose (see section 3). Consult your doctor before you continue.
Saxenda® can be used as an adjunct to a healthy nutrition and increased physical activity for weight management in adolescents from the age of 12 years and above who have:
• obesity (diagnosed by your doctor)
• body weight above 60 kg
You should only continue using Saxenda® if you have lost at least 4% of your BMI after 12 weeks on the 3.0 mg/day dose or maximum tolerated dose (see section 3). Consult your doctor before you continue.
Diet and exercise
Your doctor will start you on a diet and exercise programme. Stay on this programme while you are using Saxenda®.
Do not use Saxenda®
Warnings and precautions
Talk to your doctor, pharmacist or nurse before using Saxenda®.
The use of Saxenda® is not recommended if you have severe heart failure.
There is little experience with this medicine in patients of 75 years and older. It is not recommended if you are 75 years or older.
There is little experience with this medicine in patients with kidney problems. If you have kidney disease or are on dialysis, consult your doctor.
There is little experience with this medicine in patients with liver problems. If you have liver problems, consult your doctor.
This medicine is not recommended if you have a severe stomach or gut problem which results in delayed stomach emptying (called gastroparesis), or if you have an inflammatory bowel disease.
People with diabetes
If you have diabetes, do not use Saxenda® as a replacement for insulin.
Inflammation of the pancreas
Talk to your doctor if you have or have had a disease of the pancreas.
Inflamed gall bladder and gallstones
If you lose substantial weight, you are at a risk of gallstones and thereby inflamed gall bladder. Stop taking Saxenda® and contact a doctor immediately if you experience severe pain in your upper abdomen, usually worst on the right side under the ribs. The pain may be felt through to your back or right shoulder. See section 4.
Thyroid disease
If you have thyroid disease, including thyroid nodules and enlargement of the thyroid gland, consult your doctor.
Heart rate
Talk to your doctor if you have palpitations (you feel aware of your heartbeat) or if you have feelings of a racing heartbeat while at rest during Saxenda® treatment.
Loss of fluid and dehydration
When starting treatment with Saxenda®, you may lose body fluid or become dehydrated. This may be due to feeling sick (nausea), being sick (vomiting) and diarrhoea. It is important to avoid dehydration by drinking plenty of fluids. Talk to your doctor, pharmacist or nurse if you have any questions or concerns. See section 4.
Children and adolescents
The safety and efficacy of Saxenda® in children below 12 years of age has not been studied.
Other medicines and Saxenda®
Tell your doctor, pharmacist or nurse if you are taking, have recently taken or might take any other medicines.
In particular, tell your doctor, pharmacist or nurse if:
Pregnancy and breast-feeding
Do not use Saxenda® if you are pregnant, think that you might be pregnant or are planning to have a baby. This is because it is not known if Saxenda® may affect the baby.
Do not breast-feed if you are using Saxenda®. This is because it is not known if Saxenda® passes into breast milk.
Driving and using machines
Saxenda® is unlikely to affect your ability to drive and use machines. Some patients may feel dizziness when taking Saxenda® mainly during the first 3 months of treatment (see section ‘Possible side effects’). If you feel dizziness be extra careful while driving or using machines. If you need any further information, talk to your doctor.
Important information about some of the ingredients of Saxenda®
This medicine contains less than 1 mmol sodium (23 mg) per dose, that it is to say essentially ‘sodium-free’.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Serious side effects
Some severe allergic reactions (anaphylaxis) have been reported rarely in patients using Saxenda®. You should see your doctor straight away if you get symptoms such as breathing problems, swelling of face and throat and a fast heartbeat.
Cases of inflammation of the pancreas (pancreatitis) have been reported uncommonly in patients using Saxenda®. Pancreatitis is a serious, potentially life-threatening medical condition.
Stop taking Saxenda® and contact a doctor immediately if you notice any of the following serious side effects:
Severe and persistent pain in the abdomen (stomach area) which might reach through to your back, as well as nausea and vomiting, as it could be a sign of an inflamed pancreas (pancreatitis).
Other side effects in Adults
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
Rare: may affect up to 1 in 1,000 people
Reporting of side effects
If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.
You can also report side effects directly via
The United Kingdom of Great Britain and Northern Ireland:
Yellow Card Scheme Website: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store
Ireland:
HPRA Pharmacovigilance Website: www.hpra.ie
By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use Saxenda® after the expiry date which is stated on the pen label and carton after ‘EXP’. The expiry date refers to the last day of that month.
Before first use: Store in a refrigerator (2°C to 8°C). Do not freeze. Keep away from the freezer compartment.
Once you start using the pen: You can keep the pen for 1 month when stored at a temperature below 30°C or in a refrigerator (2°C to 8°C). Do not freeze. Keep away from the freezer compartment.
When you are not using the pen, keep the pen cap on in order to protect it from light.
Do not use this medicine if the solution is not clear and colourless or almost colourless.
Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.
What Saxenda® contains
What Saxenda® looks like and contents of the pack
Saxenda® is supplied as a clear and colourless or almost colourless solution for injection in a pre-filled pen. Each pen contains 3 ml solution and is able to deliver doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg and 3.0 mg.
Saxenda® is available in pack sizes containing 1, 3 or 5 pens. Not all pack sizes may be marketed. Needles are not included.
Marketing Authorisation Holder and Manufacturer
Novo Nordisk A/S
Novo Allé
DK-2880 Bagsværd
Denmark
Other sources of information
Detailed information on this medicine is available on the European Medicines Agency website: http://www.ema.europa.eu
This leaflet was last revised in 11/2021 (NI) and 01/2022 (GB)
Saxenda®, NovoFine® and NovoTwist® are trademarks owned by Novo Nordisk A/S, Denmark© 2021 Novo Nordisk A/S
Pay special attention to these notes as they are important for safe use of the pen.
Saxenda Patient Information Leaflet